Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;33(6):e13986.
doi: 10.1111/dth.13986. Epub 2020 Aug 6.

Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review

Affiliations

Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review

Farnoosh Seirafianpour et al. Dermatol Ther. 2020 Nov.

Abstract

COVID-19 had a great impact on medical approaches among dermatologist. This systematic review focuses on all skin problems related to COVID-19, including primary and secondary COVID-related cutaneous presentations and the experts recommendations about dermatological managements especially immunomodulators usage issues. Search was performed on PubMed, Scopus, Embase and ScienceDirect. Other additional resources were searched included Cochrane, WHO, Medscape and coronavirus dermatology resource of Nottingham university. The search completed on May 3, 2020. Three hundred seventy-seven articles assigned to the inclusion and exclusion groups. Eighty-nine articles entered the review. Primary mucocutaneous and appendageal presentations could be the initial or evolving signs of COVID-19. It could be manifest most commonly as a maculopapular exanthamatous or morbiliform eruption, generalized urticaria or pseudo chilblains recognized as "COVID toes" (pernio-like acral lesions or vasculopathic rashes). During pandemic, Non-infected non-at risk patients with immune-medicated dermatologic disorders under treatment with immunosuppressive immunomodulators do not need to alter their regimen or discontinue their therapies. At-risk o suspected patients may need dose reduction, interval increase or temporary drug discontinuation (at least 2 weeks). Patients with an active COVID-19 infection should hold the biologic or non-biologic immunosuppressives until the complete recovery occur (at least 4 weeks).

Keywords: COVID-19; alopecia; biologic; collagen vascular disorder; corona virus; cosmetic procedure; cutaneous; cutaneous manifestation; dermatitis; dermatology; drug reaction; eczema; health care staff; hidradenitis suppurativa; immunobullous; immunomodulator; immunosupressant; immunosupressive; novel human coronavirus (SARS-CoV-2); pandemic considerations; papulosquamous; pemphigus; psoriasis; recommendation; skin; skin manifestation; skin rheumatologic disorder; special; specific skin diseases; surgical procedure; systematic review; systemic treatment; teledermatology; visits.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

References

    1. Galvan Casas C, Catala A, Carretero Hernandez G, et al. Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183:71‐77. - PMC - PubMed
    1. Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. J Am Acad Dermato. 2020;83(2):563‐578. 10.1016/j.jaad.2020.04.024. - DOI - PubMed
    1. Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID‐19 pandemic. J Dermatol Treat. 2020;31:317‐318. - PubMed
    1. Arduino PG, Broccoletti R, Carbone M, et al. The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: a preliminary evaluation. J Oral Pathol Med. 2020;49(2):177‐180. - PubMed
    1. Elston DM. Occupational skin disease among health care workers during the coronavirus (COVID‐19) epidemic. J Am Acad Dermatol. 2020;82(5):1085‐1086. - PMC - PubMed

Publication types

MeSH terms

Substances